Evicenter
P&T meetings

Tirabrutinib

Primary central nervous system lymphoma

Regulatory submission
NDA submitted December 2025
Last updated
72 sources

Clinical evidence

Long-term treatment and neurotoxicity case series

5 evidence topics · 1 source

Objective
Location and study date

No evidence found.

Study design
Eligibility criteria

Not applicable.

Treatment
Study outcomes
Rationale for using clinical response as an observed outcome

Not applicable.

Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

Not applicable.

Results
Participant disposition

No evidence found.

Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

Two reported cases had long-term treatment without described neurotoxicity or leukoencephalopathy. This uncontrolled case series cannot establish the incidence of neurological toxicity or comparative neurological safety.